Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial / Ray, K.K., Colhoun, H.M., Szarek, M., Baccara-Dinet, M., Bhatt, D.L., Bittner, V.A., Budaj, A.J., Diaz, R., Goodman, S.G., Hanotin, C., Harrington, R.A., Jukema, J.W., Loizeau, V., Lopes, R.D., Moryusef, A., Murin, J., Pordy, R., Ristic, A.D., Roe, M.T., Tuñón, J., et al.. - In: THE LANCET DIABETES & ENDOCRINOLOGY. - ISSN 2213-8587. - (2019). [10.1016/S2213-8587(19)30158-5]

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Metra, Marco;
2019-01-01

File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/194119
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 298
  • ???jsp.display-item.citation.isi??? 288
social impact